KLRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: We showed that CML-RAE-1γ-Dex vaccines were able to simultaneously activate T and NK cells via the NKG2D/NKG2D-L pathway, leading to robust anti-CML effects in vitro and in vivo.